目的：探讨自体细胞因子诱导的杀伤（cytokine-induced killer，CIK）细胞对恶性肿瘤患者免疫功能和生活质量的影响。 方法： 回顾性分析在我院经过CIK细胞治疗的58例恶性肿瘤患者临床资料，流式细胞仪检测患者治疗前后外周血CD3+、CD3+CD4+、CD3+CD8+、CD3-CD16+ CD 56+和CD3+CD16+ CD 56+细胞的表达水平；42例患者治疗前后采用世界卫生组织生活质量测定简表(WHOQOL-BREF)分别进行问卷调查；治疗过程中监测相关的不良反应。 结果： 患者CIK细胞培养液体取样标本中CD3+总T淋巴细胞、CD3+CD4+T辅助淋巴细胞以及CD3+CD8+T抑制淋巴细胞的亚群水平分别为（8279±11.98）%、（30.32±11.23）%和（49.10±11.65）%，CD4+/CD8+的比值为0.67±0.34，而CD3-CD16+CD56+NK细胞和CD3+CD16+CD56+CIK细胞亚群水平分别为（16.58±11.83）%和（13.74±8.66）%。与治疗前相比，治疗后的患者外周血中CD3+总T淋巴细胞亚群、CD3+CD4+T辅助淋巴细胞亚群、CD3+CD8+T抑制淋巴细胞亚群和CD3+CD16+ CD 56+CIK细胞亚群水平均明显升高(P<0.05)，CD3-CD16+ CD 56+NK细胞亚群水平较治疗前下降(P<0.05)。经过CIK细胞治疗后，患者的生理、心理、社会关系和环境关系均得到很好的改善(P<0.05)。自体CIK细胞治疗过程中不良反应发生率低，均可控制。 结论： 自体CIK细胞治疗增强了患者的免疫功能，改善了患者的生活质量，且不良反应较轻。

Objective : The aim of the present study is to evaluate the effects of autologous cytokine-induced killer cells (CIK) immunotherapy on immune function and quality of life of cancer patients. Methods: We performed a retrospective analysis of 58 cancer patients who received CIK immunotherapy in our hospital. The T lymphocyte in their peripheral blood samples drew before and after the treatment were analyzed by flow cytometry for CD3+, CD3+CD4+, CD3+CD8+,CD3-CD16+CD56+ and CD3+CD16+CD56+ subpopulations. Patients were assessed with the WHO QOL-BREF questionnaires to evaluate their quality of life. Treatment-related adverse reactions during treatment were also surveyed. Results: In the culture for generating CIK, the levels of CD3+ T lymphocytes, CD3+CD4+ T helper cells, CD3+CD8+ cytotoxic T cells were (82.79±11.98)%, (30.32±11.23)%, and (49.10±11.65)% respectively. The ratio of CD4+ and CD8+ T cells was 0.67±0.34. Notably, the levels of CD3+CD16+CD56+ CIK cells and CD3-CD16+CD56+ NK cells were (16.58±11.83)% and (13.74±8.66)%. Comparing the two peripheral blood samples from each patient, the percentages of CD3+ T lymphocytes, CD3+CD4+ T helper cells, CD3+CD8+ cytotoxic T cells, and CD3+CD16+CD56+CIK subsets were all significantly increased after the treatment (P<0.05), whereas the percentage of CD3-CD16+CD56+NK cell percentage decreased significantly (P<0.05). The QOL-BREF of patients were also improved significantly (P<005), and the treatment-related adverse reactions were well-tolerated in most patients. Conclusion: CIK therapy is safe and effective in improving quality of life and immune functions of patients with malignant tumors.

深圳市卫生计生系统科研项目资助（No. 201402025)